PMID- 35411246
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220413
IS  - 2156-6976 (Print)
IS  - 2156-6976 (Electronic)
IS  - 2156-6976 (Linking)
VI  - 12
IP  - 3
DP  - 2022
TI  - RP11-867G2.8 promotes EMT and chordoma malignant phenotypes by enhancing FUT4 
      mRNA stability and translation.
PG  - 1264-1281
AB  - Chordoma is a rare bone tumor, and the recurrence rate of chordoma is high, the 
      treatment is difficult, and the prognosis is poor. Therefore, it is of great 
      significance to find key target genes for the treatment of chordoma. Microarray 
      was used to analyze the significant gene associated with chordoma. Western blot 
      and RT-PCR were used to detect protein and mRNA expression levels of RP11-867G2.8 
      and FUT4. Fluorescence in situ hybridization (FISH) assay was used to locate the 
      position of RP11-867G2.8 in chordoma cells. MTT assay, colony formation assay, 
      transwell assay and Xenograft Mouse Model were used to clarify the function of 
      RP11-867G2.8 and FUT4. RNA pull-down, RNA immunoprecipitation, RNA stability 
      assay and polysome profiling analysis were used to clarify the relationship 
      between RP11-867G2.8 and FUT4. We found that RP11-867G2.8 is highly expressed in 
      chordoma tissues and cells, and RP11-867G2.8 overexpression promotes the 
      malignant biological behavior of chordoma cells. RP11-867G2.8 overexpression 
      alters the expression pattern of genes modulating signaling pathway. FUT4 is 
      accumulated in chordoma tissues, and RP11-867G2.8 is antisense RNA of FUT4. 
      RP11-867G2.8 can bind to FUT4 mRNA, increasing FUT4 mRNA stability and 
      facilitating translation of FUT4. RP11-867G2.8 binds to EIF4B and PABPC1, which 
      increases the translation of FUT4. Further studies found that FUT4 silence 
      counteracts the effect of RP11-867G2.8 in vivo and in vitro. Our results suggest 
      that RP11-867G2.8 promotes the development and progression of chordoma by 
      up-regulating the expression of FUT4.
CI  - AJCR Copyright (c) 2022.
FAU - Yang, Ming
AU  - Yang M
AD  - Department of Spine Surgery, Hong Hui Hospital, Xi'an Jiaotong University College 
      of Medicine Xi'an, Shaanxi, China.
FAU - Liu, Shi Chang
AU  - Liu SC
AD  - Department of Spine Surgery, Hong Hui Hospital, Xi'an Jiaotong University College 
      of Medicine Xi'an, Shaanxi, China.
FAU - Hao, Ding Jun
AU  - Hao DJ
AD  - Department of Spine Surgery, Hong Hui Hospital, Xi'an Jiaotong University College 
      of Medicine Xi'an, Shaanxi, China.
FAU - Yan, Liang
AU  - Yan L
AD  - Department of Spine Surgery, Hong Hui Hospital, Xi'an Jiaotong University College 
      of Medicine Xi'an, Shaanxi, China.
FAU - Liu, Zhong Kai
AU  - Liu ZK
AD  - Department of Spine Surgery, Hong Hui Hospital, Xi'an Jiaotong University College 
      of Medicine Xi'an, Shaanxi, China.
FAU - Yin, Xin Hua
AU  - Yin XH
AD  - Department of Spine Surgery, Hong Hui Hospital, Xi'an Jiaotong University College 
      of Medicine Xi'an, Shaanxi, China.
LA  - eng
PT  - Journal Article
DEP - 20220315
PL  - United States
TA  - Am J Cancer Res
JT  - American journal of cancer research
JID - 101549944
PMC - PMC8984897
OTO - NOTNLM
OT  - EMT
OT  - FUT4
OT  - RP11-867G2.8
OT  - chordoma
OT  - long non-coding RNA
COIS- None.
EDAT- 2022/04/13 06:00
MHDA- 2022/04/13 06:01
PMCR- 2022/03/15
CRDT- 2022/04/12 05:31
PHST- 2021/04/04 00:00 [received]
PHST- 2022/02/23 00:00 [accepted]
PHST- 2022/04/12 05:31 [entrez]
PHST- 2022/04/13 06:00 [pubmed]
PHST- 2022/04/13 06:01 [medline]
PHST- 2022/03/15 00:00 [pmc-release]
PST - epublish
SO  - Am J Cancer Res. 2022 Mar 15;12(3):1264-1281. eCollection 2022.